Current Report Filing (8-k)
March 06 2020 - 5:04PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of
Report (Date of earliest event reported): March 4, 2020
NEMAURA
MEDICAL, INC.
(Exact name of
registrant as specified in charter)
Nevada
(State or other
jurisdiction of incorporation)
|
001-38355
|
|
46-5027260
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
57
West 57th Street
Manhattan,
NY
|
10019
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
|
|
|
|
Registrant’s
telephone number, including area code:
|
+1
(646) 416-8000
|
|
N/A
(Former
name or former address, if changed since last report)
|
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following
provisions:
[_] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant
to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[_] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
Common
Stock
|
NMRD
|
The
Nasdaq Stock Market LLC
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01.
Entry into a Material Definitive Agreement.
As reported
by Nemaura Medical, Inc., a Nevada corporation (the “Company”) on its Current Report on Form 8-K filed with the Securities
and Exchange Commission on October 19, 2018, the Company entered into an Equity Distribution Agreement (the “Agreement”)
with Maxim Group LLC as sales agent (“Maxim”), pursuant to which the Company may offer and sell, from time to time,
through Maxim up to $20,000,000 in shares of its common stock, par value $0.001 per share.
On March 4,
2020, the Company and Maxim entered into an amendment (the “Amendment”) to the Agreement, pursuant to which the parties
agreed, that notwithstanding anything in the Agreement to the contrary, the Agreement will remain in full force and effect without
a specific time-period term, provided that either the Company or Maxim may terminate the Agreement upon ten (10) days’ prior
written notice to the other party. No other changes to the Agreement were made by the Amendment.
The foregoing
description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of
the Amendment, a copy of which is filed hereto as Exhibit 10.1 and is incorporated by reference herein.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Dated: March 6, 2020
|
Nemaura Medical, Inc.
|
|
|
|
|
|
By:
|
/s/ Dewan F. H. Chowdhury
|
|
|
Name:
Title:
|
Dewan F. H. Chowdhury
Chief Executive Officer
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024
